<DOC>
	<DOCNO>NCT02946437</DOCNO>
	<brief_summary>Feasibility safety short term application sevoflurane patient SAH treat aneurysm coil clip set neurointensive care unit .</brief_summary>
	<brief_title>Sevoflurane Subarachnoidal Haemorrhage</brief_title>
	<detailed_description>After admission ICU , coil / clip intervention perform , patient screen eligibility . When patient come back ICU , successful aneurysm coil clipping , baseline ( cerebral blood flow ( CBF ) measurement conduct near infrared spectroscopy ( NIRS ) indocyanine green ( ICG ) dye dilution ( NeMo®System ) . Data artificial ventilation , systemic cerebral parameter collect continuously online monitoring , start baseline stop discharge ICU . Sevoflurane vaporize administrated MIRUS™System directly inspiratory part ventilation circuit next 4 hour . After 1 hour postconditioning sevoflurane , measurement CBF NIRS ICG dye dilution ( NeMo®System ) , well 1 hour stop postconditioning sevoflurane . In follow 14 day stay ICU , standard monitoring parameter , appearance vasospasm brain oedema record . Besides continuous online monitoring , one measurement NIRS ICG dilution laboratory assessment perform daily . At day 7±2 day 14±2 bleeding MRI CT examination perform , accord clinical condition patient , detect secondary brain injury , ischemia brain oedema . At ICU discharge , neurological outcome ass apply GOS . Important : measurement CBF NIRS ICG dye ( NeMo®System ) 1 hour postconditioning sevoflurane measurement additionally standard monitoring patient suffer severe SAH .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Patients either sex aged 1885 year Patients severe aneurysmal SAH , Hunt/Hess 3 5 . The ruptured aneurysm successfully exclude coil clip Sedation mechanical ventilation necessary due clinical situation ICP monitoring use due clinical situation ICP &lt; 20mmHg without medical treatment Systolic blood pressure value ( BP syst ) &gt; 120 mmHg need catecholamine Female patient childbearing potential negative pretreatment serum pregnancy test Informed consent obtain Significant kidney disease , define plasma creatinine &gt; 120 µmol/l Significant liver disease , define AspartateAminotransferase ( AST ) &gt; 200 U/l Significant elongation QTc interval : female &lt; 470 msec/ male &lt; 450 msec ; base 'Bazett 's Formula ' History epilepsia and/ occur seizure aneurysm rupture Pneumocephalus surgery exclude CT scan perform immediately clip History allergic disorder History , relatives history malignant hyperthermia History sign neuromuscular disease Preexisting disability Patients participate interventional clinical trial within last 30 day start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>severe SAH</keyword>
	<keyword>prevention vasospasm and/ brain oedema</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Postconditioning</keyword>
</DOC>